Shanghai - Delayed Quote CNY

TIANTAN BIO (600161.SS)

19.21
+0.05
+(0.26%)
At close: 3:00:03 PM GMT+8
Loading Chart for 600161.SS
  • Previous Close 19.16
  • Open 19.18
  • Bid 19.20 x --
  • Ask 19.21 x --
  • Day's Range 19.11 - 19.25
  • 52 Week Range 18.88 - 27.60
  • Volume 15,258,859
  • Avg. Volume 21,229,432
  • Market Cap (intraday) 37.985B
  • Beta (5Y Monthly) 0.65
  • PE Ratio (TTM) 25.96
  • EPS (TTM) 0.74
  • Earnings Date Apr 26, 2025
  • Forward Dividend & Yield 0.15 (0.78%)
  • Ex-Dividend Date Jun 20, 2024
  • 1y Target Est --

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products. Beijing Tiantan Biological Products Co., Ltd. was founded in 1966 and is headquartered in Beijing, China.

www.tiantanbio.com

5,298

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600161.SS

View More

Performance Overview: 600161.SS

Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600161.SS
6.29%
SSE Composite Index (000001.SS)
0.69%

1-Year Return

600161.SS
23.21%
SSE Composite Index (000001.SS)
7.21%

3-Year Return

600161.SS
31.85%
SSE Composite Index (000001.SS)
9.42%

5-Year Return

600161.SS
3.12%
SSE Composite Index (000001.SS)
16.45%

Compare To: 600161.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600161.SS

View More

Valuation Measures

Annual
As of 5/12/2025
  • Market Cap

    37.89B

  • Enterprise Value

    35.74B

  • Trailing P/E

    25.89

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.25

  • Price/Book (mrq)

    3.33

  • Enterprise Value/Revenue

    5.83

  • Enterprise Value/EBITDA

    14.62

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    24.10%

  • Return on Assets (ttm)

    9.58%

  • Return on Equity (ttm)

    14.38%

  • Revenue (ttm)

    6.13B

  • Net Income Avi to Common (ttm)

    1.48B

  • Diluted EPS (ttm)

    0.74

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.28B

  • Total Debt/Equity (mrq)

    0.87%

  • Levered Free Cash Flow (ttm)

    -1.96B

Research Analysis: 600161.SS

View More

Company Insights: 600161.SS

Research Reports: 600161.SS

View More

People Also Watch